Panel Session
This session will bring together leaders developing microbiome and phage-based therapies to explore how microbiome science is being translated into commercially viable products and clinical impact for patients.
Clare Trippett is Principal Strategic Opportunities Manager at CPI, a deep tech innovation centre that helps companies to develop, scale up and commercialise new products and processes. Clare holds a PhD in microbiome science and has worked in the biopharma and biotech industry for over 20 years. She has served on multiple advisory committees focused on engineering biology, microbiome and phage innovations, and has given evidence in the House of Lords Science and Technology Committee’s session on the antimicrobial potential of bacteriophages. In her current role at CPI Clare’s focus is on building large scale strategic opportunities to address industry challenges, support long term business growth and have a positive impact on society.
Adam has been involved in the development of novel live biological medicines for over 20 years, including both live bacterial therapeutics and phage-based therapies across IBD, oncology and infectious disease areas. He advanced the first engineered phage-based therapy into clinical development, targeting multi-drug resistant bacterial infections. At Microbiotica he leads all aspects of pre-clinical development, including the manufacturing of their defined live bacterial therapeutics, with a combination therapy with immune checkpoint inhibitor drugs for the treatment of advanced melanoma, and a therapy for the treatment of ulcerative colitis currently in clinical development.
Dr Joanna Wiecek is a biotech leader with over 15 years of experience in innovation, R&D, microbiome science and antimicrobial resistance. She previously served as Chief Scientific Officer at CircaGene and has worked with organisations including Dyson, GSK, P&G, Wellcome Trust, LGC and CARB-X.
As Clinical Study Lead at Covance, Joanna led large multinational, multicentre clinical studies in collaboration with companies such as Bayer and Sanofi. At Wellcome, she managed and de-risked the CARB-X research portfolio, providing scientific and technical support to life sciences start-ups including T2 Biosystems and HelixBind.
Joanna also contributed to the development of the WHO Essential Diagnostics List and helped deliver Target Product Profiles for infectious disease diagnostic devices, with related guidelines published by WHO in January 2020.
